SUNNYVALE, Calif. and YOKNEAM, ISRAEL – September 21, 2015 – Mellanox® Technologies, Ltd. (NASDAQ: MLNX), today announced that the HPC4Health Consortium, led by The Hospital for Sick Children (SickKids) and the University Health Network's Princess Margaret Cancer Centre, has selected its InfiniBand networking solutions to improve patient care and help researchers to optimize treatment with the ultimate goal of finding a cure for cancer. The end-to-end FDR 56Gb/s InfiniBand networking solution was adopted as the foundation of the center’s cancer and genomics program, to accelerate the sharing, processing and analysis of data generated from radiology imaging, medical imaging analysis, protein folding, x-ray diffraction in order to improve patient care and expedite cancer research.
HPC4Health has deployed Mellanox CloudX™ to connect the individual clouds hosted by SickKids and the Princess Margaret Cancer Centre to consolidate resources, minimize maintenance and operational costs, and improve the utilization of computational resources. Mellanox’s end-to-end FDR 56Gb/s InfiniBand solution provides high-bandwidth and a low-latency processing framework needed for the internal data network to link with the two private clouds.
“The amount of data created by today’s biomedical research environments requires computing architectures that are extremely fast, flexible and scalable,” said Jorge Gonzalez-Outeirino, technical manager and HPC4Health assistant director. “Mellanox’s CloudX and InfiniBand technology will facilitate collaboration between researchers and clinicians by enabling research to be shared. Our goal is to accelerate diagnoses and provide more personalized healthcare services for our patients.”
“Mellanox has offered support in the technical orchestration of the cluster,” said Carl Virtanen, HPC4health associate director and manager of bioinformatics services for the Princess Margaret Cancer Centre. “They have been hands-on and available to address any questions or concerns we have had with the implementation of these sophisticated computing models. Since working with Mellanox, we have seen dramatic increases in application speed and efficiency of our virtualized networks.”
“Mellanox’s complete end-to-end FDR 56Gb/s InfiniBand solutions provide the industry-leading processing throughput and bandwidth requirements needed to handle the immense computational demands being placed on today’s healthcare data centers,” said Kevin Deierling, vice president of marketing at Mellanox Technologies. “Mellanox is proud to be a part of such a noble mission to enable collaboration between researchers and clinicians to drive cutting edge advances in biomedical research, which will ultimately improve and save lives.”
- Learn more about Mellanox CloudX
- Learn more about the HPC4Health
- Follow Mellanox on Twitter, Facebook, Google+, LinkedIn, and YouTube
- Join the Mellanox Community
Mellanox Technologies is a leading supplier of end-to-end InfiniBand and Ethernet interconnect solutions and services for servers and storage. Mellanox interconnect solutions increase data center efficiency by providing the highest throughput and lowest latency, delivering data faster to applications and unlocking system performance capability. Mellanox offers a choice of fast interconnect products: adapters, switches, software, cables and silicon that accelerate application runtime and maximize business results for a wide range of markets including high-performance computing, enterprise data centers, Web 2.0, cloud, storage and financial services. More information is available at http://www.mellanox.com.
Mellanox, ConnectX and SwitchX are registered trademarks of Mellanox Technologies, Ltd. Mellanox CloudX, LinkX and Unified Fabric Manager are trademarks of Mellanox Technologies, Ltd. All other trademarks are property of their respective owners.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements related to collaboration between researchers and clinicians, the impact of such collaboration to drive cutting edge advances in biomedical research and the resulting improvement and saving of lives. These forward-looking statements are based on our current expectations, estimates and projections about our industry and business, management’s beliefs and certain assumptions made by us, all of which are subject to change. Forward-looking statements can often be identified by words such as “projects,” “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “could,” “potential,” “continue,” “ongoing,” similar expressions and variations or negatives of these words. These forward-looking statements are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause our actual results to differ materially and adversely from those expressed in any forward-looking statement. More information about the risks, uncertainties and assumptions that may impact our business is set forth in our annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 2, 2015 and in our quarterly report on Form 10-Q filed with the SEC on July 31, 2015. Other risks, uncertainties and assumptions that could cause our actual results to differ materially from those projected may be described from time to time in reports we file with the SEC, including reports on Forms 10-Q and 8-K. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.